Hycroft HYMC Q3 2025 Earnings EPS 022 Beats Estimates Northeast Region CPI Report for April 2026 Inflation Trends Under Scrutiny Heidmar HMR Climbs 1352 Resistance at 104 in Focus 20260514 India Inc Cuts ECB Borrowing by 33 in FY26 as Domestic Loans Gain Appeal Maase Inc MAAS Stalls at 1019 Consolidation Phase 20260520 Lixte LIXT Q4 2024 Posts InLine Results EPS 027 Dollar Edges Lower on Iran Deal Prospects Yen Approaches Intervention Threshold Willis WTW Delivers Q1 2026 Beat EPS 372 vs 370 Expected Ashiana Housing Reports Flat Q4 Profit at Rs 21 Crore Revenue Climbs to Rs 335 Crore FY26 Earnings Surge Bharat Taxi Becomes Worlds Largest Mobility Cooperative with 35 Million Users World Bank Report Automation May Threaten 69 of Jobs in India Signaling Labor Market Risks Novartis Raises Annual Outlook Signaling Confidence in Growth Trajectory The Hidden Pitfall of the 4 Rule Why Retirees May Need to Rethink Withdrawal Strategies NVIDIA and Fortinet Join Forces to Protect AI Workloads in Real Time Bicara Therapeutics BCAX Q1 2026 Earnings EPS Miss Overshadowed by Pipeline Progress as Stock Rises 4 COYA Q1 2026 Earnings Narrowed Loss Beats Estimates Stock Rises on Efficiency Gains JCTC Q3 2025 Earnings Loss Reported but Stock Rises A Mixed Picture for the SmallCap Distributor Burke Herbert Financial Services Corp BHRB Q1 2026 Earnings EPS Misses Estimates Amid Margin Pressures FinWise Bancorp FINW Q1 2026 Earnings EPS Misses Estimates Stock Retreats Iovance Biotherapeutics Q1 2026 Earnings EPS Misses Estimates but Stock Rises on Operational Momentum Jowell Global Ltd JWEL Surges 135 as Volume Picks Up Testing Key Resistance Sidus Space SIDU Plunges Nearly 15 as Selling Pressure Intensifies flyExclusive Inc FLYX Edges Higher as Stock Tests Key Resistance Level Cerus Corporation CERS Consolidates Near 273 as Support and Resistance Levels Hold CCID Preferred Shares Edge Higher Yield Remains Key Draw Near Par NATO Defense Spending Surge Anticipated Trump Commits 5000 Troops to Poland ASUR Q1 2026 Earnings EPS Surges Past Estimates Despite Revenue Uncertainty NewAmsterdam Pharma NAMS Faces Selling Pressure as Shares Dip 260